» Articles » PMID: 12124384

The MCpG-binding Domain of Human MBD3 Does Not Bind to MCpG but Interacts with NuRD/Mi2 Components HDAC1 and MTA2

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Jul 19
PMID 12124384
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Although mammalian MBD3 contains the mCpG-binding domain (MBD) and is highly homologous with the authentic mCpG-binding protein MBD2, it was reported that the protein does not bind to mCpG specifically. Using recombinant human wild type and mutant MBD3 proteins, we demonstrated that atypical amino acids found in MBD3 MBD, namely, His-30 and Phe-34, are responsible for the inability of MBD3 to bind to mCpG. Interestingly, although H30K/F34Y MBD3 mutant protein binds to mCpG efficiently in vitro, it was not localized at the mCpG-rich pericentromeric regions in mouse cells. We also showed that Y34F MBD2b MBD, which possesses not the mCpG-specific DNA-binding activity but the nonspecific DNA-binding activity, was localized at the pericentromeric regions. These results suggested that the mCpG-specific DNA-binding activity is largely dispensable, and another factor(s) is required for the localization of MBD proteins in vivo. MBD3 was identified as a component of the NuRD/Mi2 complex that shows chromatin remodeling and histone deacetylase activities. We demonstrated that MBD3 MBD is necessary and sufficient for binding to HDAC1 and MTA2, two components of the NuRD/Mi2 complex. It was therefore suggested that mCpG-binding-defective MBD3 has evolutionarily conserved its MBD because of the secondary role played by the MBD in protein-protein interactions.

Citing Articles

PBX/Knotted 1 homeobox-2 (PKNOX2) is a novel regulator of myocardial fibrosis.

Chen L, Li H, Liu X, Zhang N, Wang K, Shi A Signal Transduct Target Ther. 2024; 9(1):94.

PMID: 38644381 PMC: 11033280. DOI: 10.1038/s41392-024-01804-5.


Evidence that direct inhibition of transcription factor binding is the prevailing mode of gene and repeat repression by DNA methylation.

Kaluscha S, Domcke S, Wirbelauer C, Stadler M, Durdu S, Burger L Nat Genet. 2022; 54(12):1895-1906.

PMID: 36471082 PMC: 9729108. DOI: 10.1038/s41588-022-01241-6.


MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2.

Yan W, Han Q, Gong L, Zhan X, Li W, Guo Z Br J Cancer. 2022; 127(4):612-623.

PMID: 35501390 PMC: 9381593. DOI: 10.1038/s41416-022-01831-5.


CD44 alternative splicing senses intragenic DNA methylation in tumors via direct and indirect mechanisms.

Batsche E, Yi J, Mauger O, Kornobis E, Hopkins B, Hanmer-Lloyd C Nucleic Acids Res. 2021; 49(11):6213-6237.

PMID: 34086943 PMC: 8216461. DOI: 10.1093/nar/gkab437.


Methylation multiplicity and its clinical values in cancer.

Dai X, Ren T, Zhang Y, Nan N Expert Rev Mol Med. 2021; 23:e2.

PMID: 33787478 PMC: 8086398. DOI: 10.1017/erm.2021.4.